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Abstract
Introduction Levels of insulin-like growth factor (IGF)-I and its
main binding protein (IGFBP-3) have been associated with
breast cancer risk among premenopausal women. However,
associations of IGFBP-3 levels with breast cancer risk have
been inconsistent, possibly due to the different predominant
forms of circulating IGFBP-3 (intact versus fragmented) that
were measured in these studies. Here, we examine the
association of breast cancer risk factors with intact and total
IGFBP-3 levels.
Methods This cross-sectional study includes 737
premenopausal women recruited at screening mammography.
Plasma intact and total IGFBP-3 and IGF-I levels were
measured by enzyme-linked immunosorbent assay methods.
Percent and absolute breast density were estimated using a
computer-assisted method. The associations were evaluated
using generalized linear models and Pearson (r) or Spearman
(rs) partial correlation coefficients.
Results Means ± standard deviations of intact and total IGFBP-
3 levels (ng/mL) were 1,044 ± 234 and 4,806 ± 910,
respectively. Intact and total IGFBP-3 levels were correlated
with age and smoking. Levels of intact IGFBP-3 were negatively
correlated with waist-to-hip ratio (WHR) (r = -0.128; P  =
0.0005), parity (rs = -0.078; P = 0.04), and alcohol intake (r = -
0.137; P = 0.0002) and positively correlated with energy intake
(r = 0.075; P = 0.04). In contrast, total IGFBP-3 levels were
positively correlated with WHR (r = 0.115; P = 0.002), parity (rs
= 0.089; P = 0.02), body mass index (BMI) (r = 0.115; P =
0.002), physical activity (r = 0.118; P = 0.002), and IGF-I levels
(r = 0.588; P < 0.0001) and negatively correlated with percent
or absolute breast density (r = -0.095; P = 0.01 and r = -0.075;
P = 0.04, respectively).
Conclusion Our data show that associations of some breast
cancer risk factors with intact levels of IGFBP-3 are different
from those with total (intact and fragmented) IGFBP-3 levels.
These findings suggest that different molecular forms of IGFBP-
3 may bear different relations to premenopausal breast cancer
risk.
Introduction
Members of the insulin-like growth factor (IGF) family have
been suggested to play a role in the occurrence of cancer at
various sites, including the breast [1]. In particular, laboratory
studies showed that IGF-I is able to exert mitogenic and antia-
poptotic effects on normal and abnormal breast cells [2].
These results are consistent with the systematic reviews
reporting that higher levels of IGF-I are associated with an
BMI = body mass index; IGF = insulin-like growth factor; IGFBP-3 = insulin-like growth factor-binding protein-3; MET, metabolic equivalent; OR = 
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increased breast cancer risk among premenopausal women
(reviewed in [3]).
In contrast, associations of levels of total (intact and frag-
mented) IGF-binding protein-3 (IGFBP-3), the main binding
protein of circulating IGF-I, with risk of breast cancer are con-
flicting and range from a protective association in some stud-
ies to an elevated risk in others (reviewed in [3]). Similarly,
several studies have examined the association of breast can-
cer risk factors, such as personal characteristics, including life-
style factors, and mammographic breast density, with total
IGFBP-3 levels and found inconsistent results [4-13].
At the cellular level, IGFBP-3 has been found to either sup-
press or enhance the action of IGF-I and these effects are reg-
ulated, at least in part, by the presence of IGFBP proteases
[14]. As a result, it has been proposed that the divergence in
risk estimates among studies could be due to the predominant
circulating forms of IGFBP-3 (intact versus fragmented) that
have been measured. This notion was examined by Rinaldi and
colleagues [15] in a population of young women, and their
results suggested that high levels of functional IGFBP-3,
which are composed of intact IGFBP-3 and some fragments
of IGFBP-3, could be associated with a reduction of breast
cancer risk (odds ratio [OR] = 0.54) whereas high levels of
total IGFBP-3 could be associated with an increased risk of
breast cancer (OR = 1.47). Thus, the variation in intact/func-
tional versus total IGFBP-3 levels among subjects may differ-
ently modulate the risk of breast cancer.
The aim of this study was to examine whether circulating levels
of intact IGFBP-3 and total IGFBP-3 were differently associ-
ated with several breast cancer risk factors, including mammo-
graphic breast density, a strong and independent breast
cancer risk indicator [16]. To our knowledge, no other study
has examined these associations with different molecular
forms of IGFBP-3.
Materials and methods
Study population and recruitment procedures
Details of the study design and methods have been published
elsewhere [6]. Briefly, the study subjects for the present anal-
ysis were premenopausal women who received a screening
mammogram between February and December 2001 at the
Clinique radiologique Audet (Québec, QC, Canada). The
study focused only on premenopausal women because in pre-
vious analyses of our data the associations of total IGF-I and
IGFBP-3 levels with breast density were observed only among
these women [6]. Women were considered premenopausal if
they had at least one natural menstrual cycle within 12 months
or were younger than 48 years old (if a nonsmoker) or 46 years
old (if a smoker) after hysterectomy without bilateral oophorec-
tomy [17]. Exclusion criteria included the following: diabetes
mellitus; dwarfism/acromegaly; thyroid, adrenal or hepatic dis-
ease; pregnancy; use of hormonal derivatives in the last 3
months before mammography; ever use of tamoxifen or
raloxifene; personal history of cancer; or breast surgery.
A total of 787 premenopausal women were found to be eligi-
ble. Among these women, 2 declined participation, 2 could not
provide film mammograms, and 10 had incomplete answers
for some breast cancer risk factors. In the remaining 773
women, 36 did not give authorization for blood banking of
samples for further study. Therefore, a total of 737 women
were included in the present analysis. This study was reviewed
and approved by the research ethics committee of the Centre
hospitalier affilié universitaire de Québec.
Data collection
At the radiology clinic, a trained nurse measured the women's
weight (kilograms), height (centimetres), and waist and hip cir-
cumferences (centimetres) and collected 20 mL of blood.
Known or suspected breast cancer risk factors were docu-
mented by a telephone interview and included reproductive
and menstrual history, family history of breast cancer, personal
history of breast biopsies, past use of contraceptives and hor-
mone replacement therapy, smoking status, alcohol intake,
education, and physical activity. The levels of physical activity
in metabolic equivalent-hours per week were assessed using
the validated and reproducible Nurses' Health Study II Activity
and Inactivity Questionnaire [18]. Finally, each woman com-
pleted a validated [19] and self-administered semiquantitative
food frequency questionnaire (97GP copyrighted at Harvard
University, Boston, MA, USA). Food intake data obtained
through the questionnaire were translated into nutrient intake,
including energy intake (kilocalories per day), at the Channing
Laboratory of Harvard University.
All mammograms were scanned at 260 μm/pixel with a Kodak
Lumiscan85 digitizer (Eastman Kodak Company, Rochester,
NY, USA). Then, for each woman, the proportion of the breast
showing tissue density (percent density in percentage) and
the absolute amount of dense tissue (absolute density in
square centimetres) were assessed by one trained author
(CD) from the craniocaudal view of a randomly chosen breast.
This assessment was performed using a computer-assisted
method without any information on the women [20]. Variability
in the assessment of breast density was as follows: the within-
batch intraclass correlation coefficients (n = 210 duplicate
images) were 0.98 and 0.98 and the between-batch coeffi-
cients of variation (n = 10 images repeated 21 times) were 4%
and 5% for percent and absolute breast density measure-
ments, respectively.
At the time of blood collection, blood constituents were rapidly
aliquoted and stored at -80°C until analysis. Under the super-
vision of one of us (MP), plasma levels of total IGF-I, total
IGFBP-3, and intact IGFBP-3 (ng/mL) were blindly assayed by
enzyme-linked immunosorbent assay with reagents from Diag-
nostic Systems Laboratories (Webster, TX, USA). DetailedAvailable online http://breast-cancer-research.com/content/10/3/R42
Page 3 of 8
(page number not for citation purposes)
methods have been published elsewhere [21]. In the present
study, a proxy of fragmented IGFBP-3 levels was obtained by
subtracting intact IGFBP-3 levels from the total levels of
IGFBP-3. These calculated levels of fragmented IGFBP-3 are
based on the assumptions that (a) the assay used to measure
total IGFBP-3 captures all IGFBP-3 fragments, including the
intact form, and (b) the assay used to measure intact IGFBP-
3 captures all intact IGFBP-3. The intra-batch coefficients of
variation (4 samples per batch of 39 samples for a total of 46
batches) were 10.5% and 13.2% and the between-batch
coefficients of variation were 7.9% and 10.5% for total IGF-I
and total IGFBP-3, respectively [6]. The intra- and between-
batch coefficients of variation (4 samples per batch of 39 sam-
ples for a total of 22 batches) were 8.2% and 9.4%, respec-
tively, for intact IGFBP-3.
Statistical methods
Associations of breast cancer risk factors with continuous lev-
els of intact, fragmented, and total IGFBP-3 were evaluated
with the Spearman or Pearson correlation coefficients whether
factors were treated as dichotomous or continuous variables,
respectively. Multivariate-adjusted mean IGFBP-3 levels were
assessed according to categories of variables (usually quar-
tiles) using generalized linear models. The same approach was
used to obtain mean mammographic breast density by quar-
tiles of IGFBP-3 levels. However, absolute breast density was
square-root-transformed to normalize its skewed distribution,
and means are presented as back-transformed values. All sta-
tistical analyses were carried out using the SAS software sys-
tem (SAS Institute Inc., Cary, NC, USA). Statistical
significance was based on two-sided P values.
Results
Characteristics of premenopausal women are described in
Table 1. The mean value ± standard deviation for intact
IGFBP-3 levels (1,044 ± 234 mg/mL) was clearly lower than
that of total IGFBP-3 levels (4,806 ± 910 mg/mL). The Pear-
son correlations of intact IGFBP-3 levels with fragmented and
total IGFBP-3 levels were in the opposite direction (r = -0.119;
P = 0.001 and r = 0.139; P = 0.0002, respectively). The cor-
relation between levels of fragmented and total IGFBP-3 was
very high (r = 0.967; P < 0.0001).
The multivariate-adjusted correlation of women's characteris-
tics with IGFBP-3 levels varied according to the molecular
form of the protein (Table 2). Levels of intact IGFBP-3 were
negatively correlated with waist-to-hip ratio (WHR) (r = -
0.128; P = 0.0005), alcohol intake (r = -0.137; P = 0.0002),
and parity (rs = -0.078; P = 0.04) and positively correlated with
energy intake (r = 0.075; P  = 0.04); no correlation was
observed with body mass index (BMI), physical activity, and
IGF-I levels. In contrast, fragmented and total IGFBP-3 levels
were both positively correlated with BMI (r = 0.124; P  =
0.0008 and r = 0.115; P = 0.002), WHR (r = 0.156; P <
0.0001 and r = 0.115; P = 0.002), physical activity (r = 0.097;
P = 0.009 and r = 0.118; P = 0.002), parity (rs = 0.110; P =
0.003 and rs = 0.089; P = 0.02), and IGF-I levels (r = 0.588;
P < 0.0001 and r = 0.588; P < 0.0001). Moreover, frag-
mented IGFBP-3 levels were positively correlated with alcohol
intake and negatively correlated with energy intake. Finally,
intact, fragmented, or total IGFBP-3 levels were all positively
correlated with age and negatively correlated with smoking
(although the correlation was not statistically significant for
smoking with intact IGFBP-3 levels, P = 0.09).
Weight, waist circumference, and hip circumference were
negatively correlated with intact IGFBP-3 levels and positively
correlated with fragmented and total IGFBP-3 levels after
adjustment for age, alcohol and energy intakes, physical activ-
ity, parity, smoking, and IGF-I levels. These correlations were
statistically significant, except for the one between intact
IGFBP-3 levels and hip circumference (data not shown).
No association of age at menarche, number of full-term preg-
nancies, age at first full-term pregnancy, lactation, family his-
tory of breast cancer, number of breast biopsies, education,
past use of oral contraceptives, past use of hormone replace-
ment therapy, or height was observed with intact, fragmented,
and total IGFBP-3 levels (data not shown). Moreover, all varia-
bles found to be correlated with intact, fragmented, or total
Table 1
Description of the study population (n = 737)
Mean ± SD or Percentage
Growth factors
Total IGF-I, ng/mL 224.0 ± 63.7
Intact IGFBP-3, ng/mL 1,044 ± 234
Fragmented IGFBP-3, ng/mL 3,762 ± 908
Total IGFBP-3, ng/mL 4,806 ± 910
Characteristics
Age at mammography, years 46.8 ± 4.6
Body mass index, kg/m2 25.2 ± 4.5
Waist-to-hip ratio 0.78 ± 0.06
Alcohol intake, drinks/week 3.4 ± 3.8
Energy intake, kilocalories/day 1,905 ± 514
Physical activity, MET-hours/week 27.2 ± 22.2
Parity, parous percentage 75.9
Smoking, current percentage 14.9
Mammographic breast density
Percent density, percentage 42.4 ± 24.4
Absolute density, cm2 47.0 ± 28.8
IGF, insulin-like growth factor; IGFBP-3, insulin-like growth factor-
binding protein-3; MET, metabolic equivalent; SD, standard 
deviation.Breast Cancer Research    Vol 10 No 3    Diorio et al.
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Table 2
Means and correlations of IGFBP-3 levels with IGF-I levels and women's characteristics
Adjusted means of IGFBP-3 levelsa
Number Intact, ng/mL Fragmented, ng/mL Total, ng/mL
Total IGF-I, ng/mL
≤179.6 185 1,051 3,081 4,132
179.7–218.1 184 1,040 3,587 4,627
218.2–260.7 184 1,033 3,935 4,968
> 260.7 184 1,051 4,451 5,502
rb (P) 0.010 (0.78) 0.554 (< 0.0001) 0.555 (< 0.0001)
rb (P)a 0.023 (0.53) 0.588 (< 0.0001) 0.588 (< 0.0001)
Age at mammography, years
≤44 221 1,007 3,673 4,680
45–47 168 1,025 3,746 4,770
48–50 200 1,062 3,821 4,883
> 50 148 1,096 3,835 4,931
rb (P) 0.083 (0.02) 0.028 (0.46) 0.049 (0.19)
rb (P)a 0.113 (0.002) 0.104 (0.005) 0.139 (0.0002)
Body mass index, kg/m2
≤22.0 186 1,071 3,680 4,750
22.1–24.4 187 1,057 3,671 4,728
24.5–27.4 183 1,003 3,771 4,775
> 27.4 181 1,044 3,932 4,976
rb (P) -0.070 (0.06) 0.153 (< 0.0001) 0.134 (0.0003)
rb (P)a -0.024 (0.52) 0.124 (0.0008) 0.115 (0.002)
Waist-to-hip ratio
≤0.740 184 1,106 3,620 4,726
0.741–0.780 196 1,062 3,708 4,770
0.781–0.820 185 987 3,685 4,671
> 0.820 172 1,017 4,061 5,078
rb (P) -0.139 (0.0001) 0.188 (< 0.0001) 0.152 (< 0.0001)
rb (P)a -0.128 (0.0005) 0.156 (< 0.0001) 0.115 (0.002)
Alcohol intake, drinks/weekAvailable online http://breast-cancer-research.com/content/10/3/R42
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Non-drinkers 53 1,080 3,691 4,771
≤1.0 234 1,066 3,716 4,781
1.1–4.0 238 1,063 3,734 4,797
> 4.0 212 989 3,864 4,853
rb (P) -0.113 (0.002) 0.002 (0.96) -0.027 (0.46)
rb (P)a -0.137 (0.0002) 0.079 (0.03) 0.035 (0.34)
Energy intake, kilocalories/day
≤1,564.21 185 1,023 3,807 4,830
1,564.22–1,855.02 184 1,040 3,837 4,878
1,855.03–2,199.36 184 1,031 3,756 4,787
> 2,199.36 184 1,081 3,649 4,730
rb (P) 0.058 (0.12) -0.004 (0.92) 0.011 (0.76)
rb (P)a 0.075 (0.04) -0.080 (0.03) -0.055 (0.14)
Physical activity, MET-hours/week
≤10.79 185 1,036 3,647 4,683
10.80–22.27 184 1,052 3,737 4,789
22.28–36.64 184 1,033 3,783 4,815
> 36.64 184 1,055 3,884 4,939
rb (P) 0. 077 (0.04) 0.031 (0.40) 0.050 (0.17)
rb (P)a 0.069 (0.06) 0.097 (0.009) 0.118 (0.002)
Parity
Nulliparous 178 1,079 3,616 4,695
Parous 559 1,033 3,809 4,842
rs 
c (P) -0.063 (0.09) 0.135 (0.0002) 0.121 (0.001)
rs 
c (P)a -0.078 (0.04) 0.110 (0.003) 0.089 (0.02)
Smoking status
None/ex-smoker 627 1,048 3,791 4,839
Current 110 1,020 3,598 4,618
rs 
c (P) -0.094 (0.01) -0.117 (0.001) -0.129 (0.0004)
rs 
c (P)a -0.063 (0.09) -0.090 (0.01) -0.091 (0.01)
aMeans and correlations are adjusted for variables in the table. bPearson correlation (r) between continuous variables; adjusted correlations are 
partial Pearson coefficients. cSpearman correlation (rs) between dichotomous factor and continuous levels of IGFBP-3; adjusted correlations are 
partial Spearman coefficients. IGF, insulin-like growth factor; IGFBP-3, insulin-like growth factor-binding protein-3; MET, metabolic equivalent.
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IGFBP-3 levels remained statistically significant with compara-
ble correlations after further adjustment for those factors (data
not shown).
Table 3 shows correlations of mammographic breast density
with intact, fragmented, and total IGFBP-3 levels. In unad-
justed models, we found that intact IGFBP-3 levels were pos-
itively associated with percent breast density (mean percent
breast density = 40.6, 41.6, 41.5, and 45.7; r = 0.075; P =
0.04) whereas fragmented (mean percent breast density =
47.1, 44.5, 40.4, and 37.4 %; r = -0.171; P < 0.0001) and
total (mean percent breast density = 46.3, 45.6, 39.8, and
37.6 %; r = -0.151; P < 0.0001) IGFBP-3 levels were nega-
tively associated with percent breast density. Negative associ-
ations of intact (mean absolute breast density = 48.2, 46.0,
47.0, and 46.7 cm2; r = -0.010; P = 0.79), fragmented (mean
absolute breast density = 49.3, 48.3, 46.6, and 43.7 cm2; r =
-0.092; P = 0.01), and total (mean absolute breast density =
50.2, 49.4, 45.0, and 43.3 cm2; r = -0.094; P = 0.01) IGFBP-
3 levels with absolute breast density were observed before
adjusting for confounders, although the association between
intact IGFBP-3 levels and absolute breast density did not
reach statistical significance. After adjustment for factors
included in Table 1, fragmented and total IGFBP-3 levels were
negatively correlated with percent (r = -0.105; P = 0.004 and
r = -0.095; P = 0.01) and absolute (r = -0.066; P = 0.07 and
r = -0.075; P = 0.04) breast density whereas levels of intact
IGFBP-3 were not significantly correlated with either percent
or absolute breast density. After further adjustment for age at
menarche, number of full-term pregnancies, age at first full-
term pregnancy, lactation, family history of breast cancer,
number of breast biopsies, education, past use of oral contra-
ceptives, past use of hormone replacement therapy, and
height, these correlations were all slightly stronger, and the
borderline negative correlation between absolute density and
fragmented IGFBP-3 levels became statistically significant.
Discussion
Our data suggest that, among premenopausal women, the
associations of some breast cancer risk factors with intact lev-
els of IGFBP-3 are different from those with total (intact and
fragmented) IGFBP-3 levels. Our data show that lower WHR,
lower alcohol intake, and higher energy intake or nulliparity are
associated with higher levels of intact IGFBP-3 whereas asso-
ciations in the opposite direction are observed between these
breast cancer risk factors and fragmented or total IGFBP-3
levels. Moreover, fragmented or total IGFBP-3 levels were
negatively associated with mammographic breast density, one
of the strongest known breast cancer risk factors, whereas no
such association was seen with intact IGFBP-3. These find-
ings suggest that different forms of IGFBP-3 may bear differ-
ent relations to premenopausal breast cancer risk.
This is the first epidemiologic study to examine the association
of intact and total IGFBP-3 measurements with a large set of
breast cancer risk factors, including mammographic breast
density. So far, two studies have reported on the association
of different measurements of IGFBP-3 levels with the risk of
breast cancer and found inconsistent results [15,22]. The first
case-control study of 40 cases and 40 age- and race-matched
controls among premenopausal and postmenopausal women
failed to show any association of intact, fragmented, or total
IGFBP-3 levels with the risk of breast cancer [22]. In contrast,
recent data from the New York University Women's Health
Table 3
Means and correlations of IGFBP-3 levels with mammographic breast density
Adjusted means of percent density (percentage)a Adjusted means of absolute density (cm2)a,b
Levels of IGFBP-3 Intactc Fragmentedd Totale Intactc Fragmentedd Totale
Quartile 1 (n = 185) 42.2 45.3 44.5 48.6 48.3 49.4
Quartile 2 (n = 184) 42.9 44.3 44.7 46.3 48.0 48.6
Quartile 3 (n = 184) 40.4 40.3 40.7 45.7 45.9 45.0
Quartile 4 (n = 184) 44.0 39.6 39.6 45.5 43.9 43.1
rf (P) 0.075 (0.04) -0.171 (< 0.0001) -0.151 (< 0.0001) -0.010 (0.79) -0.092 (0.01) -0.094 (0.01)
rf (P)a 0.031 (0.40) -0.105 (0.004) -0.095 (0.01) -0.029 (0.43) -0.066 (0.07) -0.075 (0.04)
rf (P)g 0.022 (0.55) -0.112 (0.003) -0.104 (0.005) -0.042 (0.26) -0.078 (0.04) -0.090 (0.02)
aMeans and correlations are adjusted for age, body mass index, waist-to-hip ratio, alcohol intake, energy intake, physical activity, parity, smoking 
status, and total IGF-I levels. bMeans of absolute density are presented as back-transformed values; square-root-transformed absolute density is 
used in the correlation. cQuartiles of intact IGFBP-3 are ≤883.80, 883.81 to 1,021.00, 1,021.01 to 1,170.50, and > 1,170.50 ng/mL. dQuartiles 
of fragmented IGFBP-3 are ≤3,137.50, 3,137.51 to 3,662.50, 3,662.51 to 4,263.00, and > 4,263.00 ng/mL. eQuartiles of total IGFBP-3 are 
≤4,183.0, 4,183.1 to 4,695.0, 4,695.1 to 5,290.0, and > 5,290.0 ng/mL. fPearson correlation between continuous variables; adjusted 
correlations are partial Pearson coefficients. gCorrelations are adjusted for age, body mass index, waist-to-hip ratio, alcohol intake, energy intake, 
physical activity, parity, smoking status, total IGF-I levels, age at menarche, number of full-term pregnancies, age at first full-term pregnancy, 
lactation, family history of breast cancer, number of breast biopsies, education, past use of oral contraceptives, past use of hormone replacement 
therapy, and height.Available online http://breast-cancer-research.com/content/10/3/R42
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Study suggested that, among young women, high levels of
functional IGFBP-3 could be associated with a reduction of
breast cancer risk whereas high levels of total IGFBP-3 could
be associated with an increased risk of breast cancer [15].
Mammographic breast density is a strong biomarker for breast
cancer [16]. Contrary to our expectations, the associations of
intact and total IGFBP-3 levels with breast density do not
seem to mirror the IGFBP-3-breast cancer associations in the
study of Rinaldi and colleagues [15]. However, both studies
differ on several points regardless of the breast density/risk
issue. In the study of Rinaldi and colleagues, women were
younger and leaner and more were nulliparous and they had
different mean levels of growth factors. Most importantly, the
measurement of functional IGFBP-3 concentrations was
assessed by ligand immunofunctional assay, which measured
the forms of IGFBP-3 that are able to bind the IGF ligand. It
has been shown that different lengths of IGFBP-3 fragments,
including the first 97 residues (1–97IGFBP-3), are capable of
binding IGFs, though with a lower affinity than intact IGFBP-3
[14,23]. In the present study, these 1–97IGFBP-3 fragments
are not detected by the assay used [21] and, thus, such frag-
ments are not contributing to our intact IGFBP-3 measure-
ment. This difference between assays may explain, at least in
part, the higher correlation between functional and total
IGFBP-3 levels (r = 0.45) in the study of Rinaldi and col-
leagues.
Meanwhile, laboratory studies showed that different molecular
forms of IGFBP-3 such as intact IGFBP-3, 1–160IGFBP-3, and
1–95IGFBP-3 fragments have different proliferative and apop-
totic activities on cells [24,25]. It has been observed that, at
the same concentration, 1–160IGFBP-3 fragments stimulate
proliferation whereas 1–95IGFBP-3 fragments inhibit prolifera-
tion of prostate carcinoma cells [24]. Moreover, 1–95IGFBP-3
fragments were shown to induce morphological changes and
apoptosis of breast carcinoma cells [25]. The 1–95IGFBP-3
fragments were suggested to inhibit, at least in part, the
mitogenic signals resulting from IGF-I receptor activation
[23,24,26,27]. These findings suggest that the proportions of
1–95IGFBP-3, 1–160IGFBP-3, and 1–264IGFBP-3 (intact IGFBP-
3) relative to total IGFBP-3 are important, and methods should
be developed to precisely measure each of these fragments
since they may have different effects on target cells. Therefore,
differences in the assay and the molecular forms of IGFBP-3
measurement may explain, to some extent, the inconsistency
between the study of Rinaldi and colleagues [15] and the
present study and the heterogeneity between studies evaluat-
ing total IGFBP-3 levels with the risk of breast cancer or its
associated risk factors [3-13].
The major strengths of this study include the reliability of
breast density measurements, the extensive information on
breast cancer risk factors, and the relatively large sample size.
However, this study also has some limitations. First, levels of
fragmented IGFBP-3 were not assayed but derived from the
difference between levels of total and intact IGFBP-3. This dif-
ference can be considered only as a proxy of all IGFBP-3 frag-
ments. Therefore, associations observed with estimated
fragmented IGFBP-3 levels have to be interpreted with cau-
tion. Nevertheless, since the association of several breast can-
cer risk factors with estimated fragmented IGFBP-3 was quite
different from their association with intact IGFBP-3, our results
suggest that further studies should measure levels of frag-
mented IGFBP-3 using specific assays and should examine
intact and fragmented IGFBP-3 separately. It has been pro-
posed that long-term storage may increase proteolytic activity
and, therefore, increase levels of fragmented IGFBP-3 [28].
However, our results were essentially unchanged after further
adjustment for the length of storage in the analysis. Second,
laboratory measurements were performed on non-fasting
blood samples. In a recent study, it has been suggested that
fasting and fed state can affect levels of IGF-I and IGFBP-3
[29]. However, our results remain similar when models were
further adjusted for the number of hours since the last meal.
Third, blood collection was not timed with a specific phase of
the menstrual cycle. However, the phase of cycle at the time
of blood collection was associated with neither IGFBP-3 lev-
els nor breast density. Moreover, further adjustment for men-
strual cycle phase at the time of blood collection (and
mammogram) had essentially no confounding effect in these
data. Fourth, because an exploratory approach was used and
multiple testing was carried out, we cannot totally exclude the
possibility that some of the findings could be due to chance.
Moreover, some of the observed correlations are weak with
uncertain clinical significance. Therefore, these data need to
be confirmed by other studies. Finally, the cross-sectional
design of the study does not allow us to determine the tempo-
rality of the relation between IGFBP-3 levels and breast cancer
risk factors.
Conclusion
The associations of several breast cancer risk factors with
IGFBP-3 levels vary in strength and even direction depending
on the molecular form of IGFBP-3. These results suggest that
different molecular forms of circulating IGFBP-3 (intact versus
fragmented) may bear different relations to the risk of breast
cancer and, possibly, of cancer at other sites. Further studies
measuring intact, fragmented, and total IGFBP-3 would help
to identify whether this molecule is a cancer risk factor, a pre-
ventive factor, or both.
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